<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39390398</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Predictors of moderate-to-severe side-effects following COVID-19 mRNA booster vaccination: a prospective cohort study among primary health care providers in Belgium.</ArticleTitle><Pagination><StartPage>1135</StartPage><MedlinePgn>1135</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1135</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09969-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 vaccine effectiveness declines months after vaccination. Therefore, it is likely that during the next few years, people may be repeatedly offered a booster vaccine to enhance humoral immunity levels. A growing number of people are questioning whether the benefits of a booster vaccine outweigh the side-effects.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims (1) to identify the most frequently reported side-effects after different doses of COVID-19 mRNA vaccines, (2) and the longest lasting symptoms; and (3) to predict the likelihood of having moderate-to-severe side-effects after a booster COVID-19 mRNA vaccine given individual- and vaccine-specific characteristics.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Secondary analysis of a prospective cohort study in primary health care providers (PHCPs) in Belgium conducted between December 2020 and December 2021, and in February-March 2023.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In nine subsequent surveys over a period of 2 years vaccine dose-number and side-effects after COVID-19 vaccines were collected. A Generalized Estimation Equations approach on the data of the first and second booster dose was used to investigate the probability of having moderate-to-severe side-effects after mRNA booster vaccination. Predictive performance of a binary classifier was assessed by looking at discrimination (i.e., quantified in terms of the area under the receiver operating characteristic curve). The final prediction model was validated using data with regard to the third booster by assessing misclassification rate, sensitivity and specificity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 11% of the PHCPs had moderate-to-severe side-effects after their booster COVID-19 mRNA vaccine. The most common side-effects of COVID-19 mRNA doses included fatigue, local pain at the injection site, general pains, and headache. These side-effects typically lasted for a median of 1 to 2 days. The final model included five predictors: sex, alcohol consumption, history of moderate-to-severe side-effects after any previous dose, recent COVID-19 infection, and the booster dose-number (first, second). Having experienced moderate-to-severe side-effects after any previous dose was the strongest predictor of moderate-to-severe side-effects following an mRNA vaccine booster, with an odds ratio (OR) of 3.64 (95% CI: 2.80-4.75). The OR for female sex was 1.49 (95% CI: 1.21-1.84) implying that females have a higher odds of moderate-to-severe side-effects following booster vaccination. The differences in effect for booster dose-number, alcohol consumption and recent COVID-19 infection was not significant.</AbstractText><AbstractText Label="CONCLUSION AND RELEVANCE" NlmCategory="CONCLUSIONS">COVID-19 mRNA booster vaccination implies a low prevalence of moderate-to-severe side-effects among PHCPs, with a short median duration of symptoms if any. The strongest predictors are a history of moderate-to-severe side-effects after any previous dose and being female. These reassuring findings can help addressing concerns about booster vaccination and encourage their uptake.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT04779424 (registration date: 2021-02-22).</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Domen</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for General Practice, Department of Family Medicine &amp; Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium. julie.domen@uantwerpen.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrams</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Global Health Institute, Department of Family Medicine &amp; Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Data Science Institute, Interuniversity Institute for Biostatistics and statistical Bioinformatics, UHasselt, Diepenbeek, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Digregorio</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research unit of Primary Care and Health, Department of General Medicine, Faculty of Medicine, University of Liège, Liège, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Ngoc</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research unit of Primary Care and Health, Department of General Medicine, Faculty of Medicine, University of Liège, Liège, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duysburgh</LastName><ForeName>Els</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scholtes</LastName><ForeName>Béatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Research unit of Primary Care and Health, Department of General Medicine, Faculty of Medicine, University of Liège, Liège, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coenen</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for General Practice, Department of Family Medicine &amp; Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04779424</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="Y">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="Y">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 mRNA booster vaccine</Keyword><Keyword MajorTopicYN="N">Side-effects</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39390398</ArticleId><ArticleId IdType="pmc">PMC11468363</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09969-8</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09969-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agency EM. EMA recommends first COVID-19 vaccine for authorisation in the EU [Internet]. 2020 [cited 2022 Mar 10]. Available from: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu</Citation></Reference><Reference><Citation>Agency EM. Spikevax (previously COVID-19 Vaccine Moderna) [Internet]. 2021 [cited 2022 Mar 10]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax</Citation></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira ED, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N Engl J Med. 2022 May 19;386(20):1910–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006787</ArticleId><ArticleId IdType="pubmed">35320659</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022 Mar 1;399(10328):924–44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Adriaenssens N, Scholtes B, Bruyndonckx R, Van Ngoc P, Verbakel JYJ, De Sutter A, et al. Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up. BMJ Open. 2022/09/20 ed. 2022 Sep 19;12(9):e065897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9485641</ArticleId><ArticleId IdType="pubmed">36123069</ArticleId></ArticleIdList></Reference><Reference><Citation>Adriaenssens N, Scholtes B, Bruyndonckx R, Verbakel JY, De Sutter A, Heytens S, et al. Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol. BMJ Open. 2022 Jan;12(1):e054688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8804304</ArticleId><ArticleId IdType="pubmed">35105642</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. Bmj. 2022;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9527398</ArticleId><ArticleId IdType="pubmed">36191948</ArticleId></ArticleIdList></Reference><Reference><Citation>Loubet P, Laureillard D, Martin A, Larcher R, Sotto A. Why promoting a COVID-19 vaccine booster dose? Anaesth Crit Care Pain Med. 2021/12/21 ed. 2021 Dec;40(6):100967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8675238</ArticleId><ArticleId IdType="pubmed">34924154</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson HJ, Gakidou E, Murray CJL. The Vaccine-Hesitant Moment. N Engl J Med. 2022 Jul 7;387(1):58–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258752</ArticleId><ArticleId IdType="pubmed">35767527</ArticleId></ArticleIdList></Reference><Reference><Citation>Booster vaccination against COVID-19 for the general population. Superior Health Council.; 2021.</Citation></Reference><Reference><Citation>COVID-19 vaccination: Autumn/Winter season 2022–2023. Superior Health Council.; 2022.</Citation></Reference><Reference><Citation>Vermeiren E, Van Loenhout JAF, Nasiadka L, Stouten V, Billuart M, Van Evercooren I, et al. Factors underlying COVID-19 booster vaccine uptake among adults in Belgium. BMC Res Notes. 2023 Nov 11;16(1):328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10640742</ArticleId><ArticleId IdType="pubmed">37951923</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziedzic A, Issa J, Hussain S, Tanasiewicz M, Wojtyczka R, Kubina R, et al. COVID-19 vaccine booster hesitancy (VBH) of healthcare professionals and students in Poland: Cross-sectional survey-based study. Front Public Health. 2022 Jul 25;10:938067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9359622</ArticleId><ArticleId IdType="pubmed">35958845</ArticleId></ArticleIdList></Reference><Reference><Citation>İkiışık H, Sezerol MA, Taşçı Y, Maral I. COVID-19 vaccine hesitancy and related factors among primary healthcare workers in a district of Istanbul: a cross-sectional study from Turkey. Fam Med Community Health. 2022 Apr 1;10(2):e001430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9039154</ArticleId><ArticleId IdType="pubmed">35470223</ArticleId></ArticleIdList></Reference><Reference><Citation>Digregorio M, Van Ngoc P, Domen J, Bognar Z, Duysburgh E, Hendrickx G, et al. Primary Healthcare Providers’ Views on Periodic COVID-19 Booster Vaccination for Themselves and Their Patients: A 2023 Nationwide Survey in Belgium. Vaccines. 2024 Jul 3;12(7):740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11281441</ArticleId><ArticleId IdType="pubmed">39066378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratzan S, Schneider EC, Hatch H, Cacchione J. Missing the Point — How Primary Care Can Overcome Covid-19 Vaccine “Hesitancy.” N Engl J Med. 2021 Jun 24;384(25):e100.</Citation><ArticleIdList><ArticleId IdType="pubmed">33951377</ArticleId></ArticleIdList></Reference><Reference><Citation>Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. Public Health. 2021 May;194:245–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7931735</ArticleId><ArticleId IdType="pubmed">33965796</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J, et al. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat Med. 2022 Nov 1;28(11):2388–97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671805</ArticleId><ArticleId IdType="pubmed">36202997</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Poverty. 2021 Dec 1;10(1):132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8590867</ArticleId><ArticleId IdType="pubmed">34776011</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Poverty. 2021 Dec 1;10(1):94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8256217</ArticleId><ArticleId IdType="pubmed">34225791</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021 Jul 1;21(7):939–49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078878</ArticleId><ArticleId IdType="pubmed">33930320</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum HG, Gee J, Liu R, Marquez PL, Zhang B, Strid P, et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet Infect Dis. 2022 Jun 1;22(6):802–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901181</ArticleId><ArticleId IdType="pubmed">35271805</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons K. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC Med. 2015 Jan 1;13(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284921</ArticleId><ArticleId IdType="pubmed">25563062</ArticleId></ArticleIdList></Reference><Reference><Citation>Stef VB. Flexible Imputation of Missing Data. [Internet]. 2018. Available from: https://stefvanbuuren.name/fimd/</Citation></Reference><Reference><Citation>Barnard JRDB. Small-Sample Degrees of Freedom with Multiple Imputation. Biometrika. 1999;86(4):948 − 55.</Citation></Reference><Reference><Citation>Salazar A, Ojeda B, Dueñas M, Fernández F, Failde I. Simple generalized estimating equations (GEEs) and weighted generalized estimating equations (WGEEs) in longitudinal studies with dropouts: guidelines and implementation in R. Stat Med. 2016 Aug 30;35(19):3424–48.</Citation><ArticleIdList><ArticleId IdType="pubmed">27059703</ArticleId></ArticleIdList></Reference><Reference><Citation>Harell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis [Internet]. Cham: Springer International Publishing; 2015 [cited 2024 Jun 10]. (Springer Series in Statistics). Available from: https://link.springer.com/10.1007/978-3-319-19425-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-19425-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendel RB, Afifi AA. Comparison of Stopping Rules in Forward “Stepwise” Regression. J Am Stat Assoc. 1977 Mar;72(357):46.</Citation></Reference><Reference><Citation>Wei P. Akaike’s Information Criterion in Generalized Estimating Equations. Biometrics. 2001;57:120–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11252586</ArticleId></ArticleIdList></Reference><Reference><Citation>Panken AM, Heymans MW. A simple pooling method for variable selection in multiply imputed datasets outperformed complex methods. BMC Med Res Methodol. 2022 Dec;22(1):214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9351113</ArticleId><ArticleId IdType="pubmed">35927610</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciensano the B institute for health. Administered vaccines by date, region, age, sex, brand and dose [Internet]. [cited 2023 Jan 1]. Available from: https://epistat.sciensano.be/covid/</Citation></Reference><Reference><Citation>Ali MD, Almadan LZ, Alghamdi RA, Alghamdi AS, Almarhoon SA, Hassan YA, et al. Evaluation of Prevalence of Side-Effects Associated with Booster Dose of mRNA-Based COVID-19 Vaccine Among Healthcare Workers in Eastern Province, Saudi Arabia: A Descriptive Cross-Sectional Study. Infect Drug Resist. 2022 Aug 1;15:4335–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9375576</ArticleId><ArticleId IdType="pubmed">35971558</ArticleId></ArticleIdList></Reference><Reference><Citation>Galanis P, Katsiroumpa A, Vraka I, Chrysagi V, Siskou O, Konstantakopoulou O, et al. Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece. Vacunas. 2023;24(3):210–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10213299</ArticleId><ArticleId IdType="pubmed">37362837</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. JAMA Netw Open. 2021 Dec 22;4(12):e2140364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8696570</ArticleId><ArticleId IdType="pubmed">34935921</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PY, Wu BJ, Su MC, Lin YH, Chiang SC, Wu JC, et al. Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose. Vaccines. 2022 Jul 13;10(7):1115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9316082</ArticleId><ArticleId IdType="pubmed">35891279</ArticleId></ArticleIdList></Reference><Reference><Citation>Klugar M, Riad A, Mekhemar M, Conrad J, Buchbender M, Howaldt HP, et al. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers. Biology. 2021 Aug 5;10(8):752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389568</ArticleId><ArticleId IdType="pubmed">34439984</ArticleId></ArticleIdList></Reference><Reference><Citation>Hin LY, Wang YG. Working-correlation-structure identification in generalized estimating equations. Stat Med. 2008/12/10 ed. 2009 Feb 15;28(4):642–58.</Citation><ArticleIdList><ArticleId IdType="pubmed">19065625</ArticleId></ArticleIdList></Reference><Reference><Citation>Interim statement on the use of additional booster doses of emergency use listed mRNA vaccines against COVID-19. [Internet]. World Health Oranization; 2022 May. Available from: https://www.who.int/news/item/17-05-2022-interim-statement-on-the-use-of-additional-booster-doses-of-emergency-use-listed-mrna-vaccines-against-covid-19</Citation></Reference><Reference><Citation>Vaccine Safety Datalink (VSD): [Internet]. Centers for Disease Control and Prevention; 2023. Available from: https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>